🇺🇸 FDA
Patent

US 10799461

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

granted A61KA61K31/704A61K47/6879

Quick answer

US patent 10799461 (Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells) held by EnGeneIC Molecular Delivery Pty Ltd expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
EnGeneIC Molecular Delivery Pty Ltd
Grant date
Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/704, A61K47/6879, A61K47/6901, A61K9/5068